<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Laboratory Corporation Of America Holdings — News on 6ix</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings</link>
<description>Latest news and press releases for Laboratory Corporation Of America Holdings on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/laboratory-corporation-of-america-holdings" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835916278dffbe2df1026d9.webp</url>
<title>Laboratory Corporation Of America Holdings</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings</link>
</image>
<item>
<title>Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-launches-fda-approved-companion-diagnostic-to-identify-patients-with-ovarian-cancer-eligible-for-keytrudar</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-launches-fda-approved-companion-diagnostic-to-identify-patients-with-ovarian-cancer-eligible-for-keytrudar</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®.iKEYTRUDA (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhib</description>
</item>
<item>
<title>Ultima Genomics releases groundbreaking TRACERx MRD data showing ppmSeq performance and unveils clinical progress of whole genome sequencing at inaugural global MRD Symposium at AACR 2026</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/ultima-genomics-releases-groundbreaking-tracerx-mrd-data-showing-ppmseq-performance-and-unveils-clinical-progress-of-whole-genome-sequencing-at-inaugural-global-mrd-symposium-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/ultima-genomics-releases-groundbreaking-tracerx-mrd-data-showing-ppmseq-performance-and-unveils-clinical-progress-of-whole-genome-sequencing-at-inaugural-global-mrd-symposium-at-aacr-2026</guid>
<pubDate>Fri, 17 Apr 2026 12:00:00 GMT</pubDate>
<description>Ultima Genomics, a developer of an innovative, ultra-high throughput sequencing architecture today announced key milestones for its ppmSeq® technology with a growing body of evidence from data presented across six abstracts, including an oral session and a plenary session at the 2026 AACR Annual Meeting in San Diego, taking place April 17–22, 2026. Highlighting the program will be initial TRACERx MRD data showcasing the performance of ppmSeq relative to ultrasensitive bespoke panels. Data from c</description>
</item>
<item>
<title>Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-launches-fda-cleared-fentanyl-test-delivering-results-in-10-minutes</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-launches-fda-cleared-fentanyl-test-delivering-results-in-10-minutes</guid>
<pubDate>Wed, 15 Apr 2026 11:00:00 GMT</pubDate>
<description>Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the Labcorp Fentanyl Urine Visual Test, the first U.S. Food and Drug Administration (FDA)-cleared rapid fentanyl test of its kind manufactured in the United States. The test delivers results in just 10 minutes, giving healthcare providers fast, actionable answers when treating suspected fentanyl exposure in emergency departments, hospitals and clinics.</description>
</item>
<item>
<title>Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-introduces-ai-powered-real-world-data-platform-with-aws-and-datavant-to-accelerate-alzheimers-research</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-introduces-ai-powered-real-world-data-platform-with-aws-and-datavant-to-accelerate-alzheimers-research</guid>
<pubDate>Tue, 14 Apr 2026 11:00:00 GMT</pubDate>
<description>Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster. Developed with Amazon Web Services (AWS) and Datavant, the platform provides access to large, diverse datasets and advanced analytics—using deidentified, privacy-protected healthcare data—designed to accelerate scientific discovery, shorten d</description>
</item>
<item>
<title>Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/childrens-hospital-of-philadelphia-and-labcorp-announce-a-collaboration-to-accelerate-access-to-advanced-pediatric-diagnostics-nationwide</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/childrens-hospital-of-philadelphia-and-labcorp-announce-a-collaboration-to-accelerate-access-to-advanced-pediatric-diagnostics-nationwide</guid>
<pubDate>Mon, 13 Apr 2026 12:30:00 GMT</pubDate>
<description>Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Children's Hospital of Philadelphia (CHOP), the nation's first pediatric hospital, announced today a strategic collaboration to accelerate the discovery, development and nationwide availability of specialized pediatric diagnostics. By combining CHOP's pediatric research and clinical expertise with Labcorp's national diagnostic infrastructure, scientific capabilities and commercialization expertise, the c</description>
</item>
<item>
<title>Labcorp to Announce First Quarter Financial Results on April 30, 2026</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-to-announce-first-quarter-financial-results-on-april-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-to-announce-first-quarter-financial-results-on-april-30-2026</guid>
<pubDate>Tue, 31 Mar 2026 20:15:00 GMT</pubDate>
<description>Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2026 before the market opens on Thursday, April 30, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the "News & Events" section of the Labcorp Investor Relations website at https://ir.labcorp.com. A link</description>
</item>
<item>
<title>Illumina and Labcorp expand collaboration to broaden access to precision oncology testing</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/illumina-and-labcorp-expand-collaboration-to-broaden-access-to-precision-oncology-testing-1</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/illumina-and-labcorp-expand-collaboration-to-broaden-access-to-precision-oncology-testing-1</guid>
<pubDate>Wed, 18 Mar 2026 13:15:00 GMT</pubDate>
<description>Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitat</description>
</item>
<item>
<title>Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-expands-collaboration-with-pathai-to-deploy-fda-cleared-digital-pathology-platform-nationwide</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-expands-collaboration-with-pathai-to-deploy-fda-cleared-digital-pathology-platform-nationwide</guid>
<pubDate>Mon, 23 Feb 2026 12:00:00 GMT</pubDate>
<description>Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations. The cloud-based technology allows pathologists to view and manage slides digitally and use AI to support key steps in the diagnostic process.</description>
</item>
<item>
<title>Labcorp Announces 2025 Fourth Quarter and Full Year Results</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-announces-2025-fourth-quarter-115000731</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-announces-2025-fourth-quarter-115000731</guid>
<pubDate>Tue, 17 Feb 2026 11:50:00 GMT</pubDate>
<description>Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter and full year ended December 31, 2025, and provided 2026 guidance.</description>
</item>
<item>
<title>Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-launches-first-fda-cleared-120000872</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-launches-first-fda-cleared-120000872</guid>
<pubDate>Wed, 11 Feb 2026 12:00:00 GMT</pubDate>
<description>Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment of Alzheimer's disease in the primary care setting. This launch further expands Labcorp's comprehensive portfolio of Alzheimer's disease blood tests, offering clinicians solutions across both primary and specialty care</description>
</item>
<item>
<title>Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-appoints-john-h-sampson-133000649</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-appoints-john-h-sampson-133000649</guid>
<pubDate>Mon, 09 Feb 2026 13:30:00 GMT</pubDate>
<description>Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026.</description>
</item>
<item>
<title>MASHNET Announces Founding of MASLD Diagnostic Coalition</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/mashnet-announces-founding-of-masld-diagnostic-coalition</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/mashnet-announces-founding-of-masld-diagnostic-coalition</guid>
<pubDate>Tue, 03 Feb 2026 14:38:00 GMT</pubDate>
<description>MASHNET, a liver Network of Excellence powered by Petauri Kinect, announced today the formation of the MASLD Diagnostic Coalition, a multistakeholder collaboration united by a shared goal to advance access and awareness of non-invasive diagnostics for metabolic dysfunction-associated steatotic liver disease (MASLD).</description>
</item>
<item>
<title>Death Clock Launches "Life Lab": An AI Health Concierge Democratizing Private-Doctor Level Care for the Mass Market</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/death-clock-launches-life-lab-an-ai-health-concierge-democratizing-private-doctor-level-care-for-the-mass-market</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/death-clock-launches-life-lab-an-ai-health-concierge-democratizing-private-doctor-level-care-for-the-mass-market</guid>
<pubDate>Mon, 02 Feb 2026 13:00:00 GMT</pubDate>
<description>Death Clock, the world's #1 longevity app, today announced the launch of Life Lab, an advanced AI health concierge designed to shift healthcare from reactive treatment to proactive prevention. This major evolution brings "Medicine 3.0" capabilities to the public, including integrated blood work from over 4,800 Labcorp, Quest, and BioReference locations and the ability for users to upload existing records from their own physicians. All blood tests also include the biomarkers necessary to calculat</description>
</item>
<item>
<title>Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-announce-fourth-quarter-financial-211500679</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-announce-fourth-quarter-financial-211500679</guid>
<pubDate>Thu, 15 Jan 2026 21:15:00 GMT</pubDate>
<description>Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.</description>
</item>
<item>
<title>Labcorp Declares Quarterly Dividend</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-declares-quarterly-dividend-115000420</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-declares-quarterly-dividend-115000420</guid>
<pubDate>Wed, 14 Jan 2026 11:50:00 GMT</pubDate>
<description>Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026.</description>
</item>
<item>
<title>Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-expands-mrd-testing-breast-120000984</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-expands-mrd-testing-breast-120000984</guid>
<pubDate>Tue, 13 Jan 2026 12:00:00 GMT</pubDate>
<description>Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians detect cancer recurrence earlier than traditional imaging. The expanded offerings include Labcorp Plasma Detect ID, a whole exome sequence-guided, personalized panel for patients with stage I–III breast cancer or stage I–IIIA non-small cell lung cancer, and the nationwide availability of Lab</description>
</item>
<item>
<title>Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/visby-engages-quest-and-labcorp-to-broaden-consumer-access-to-first-at-home-fda-authorized-pcr-test-for-stis</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/visby-engages-quest-and-labcorp-to-broaden-consumer-access-to-first-at-home-fda-authorized-pcr-test-for-stis</guid>
<pubDate>Thu, 08 Jan 2026 14:00:00 GMT</pubDate>
<description>SAN JOSE, Calif., January 08, 2026--Today, Visby Medical announced two new relationships that will expand national access to the Visby Women’s Sexual Health Test, the first, at-home, FDA-authorized PCR test for sexually transmitted infections (STIs) available to consumers, enabling immediate access to Visby’s integrated "Test-to-Treat" ecosystem. The palm-sized device delivers confidential results in just 30 minutes, providing women with a rapid response for chlamydia, gonorrhea, and trichomonia</description>
</item>
<item>
<title>NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/namsa-announces-strategic-acquisition-of-select-assets-of-the-early-development-medical-device-testing-business-of-labcorp</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/namsa-announces-strategic-acquisition-of-select-assets-of-the-early-development-medical-device-testing-business-of-labcorp</guid>
<pubDate>Thu, 08 Jan 2026 13:30:00 GMT</pubDate>
<description>NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide.</description>
</item>
<item>
<title>PracticeQ Partners With Fullscript to Streamline Lab Testing and Improve Patient Care</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/practiceq-partners-with-fullscript-to-streamline-lab-testing-and-improve-patient-care</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/practiceq-partners-with-fullscript-to-streamline-lab-testing-and-improve-patient-care</guid>
<pubDate>Tue, 06 Jan 2026 14:00:00 GMT</pubDate>
<description>SAN DIEGO, January 06, 2026--PracticeQ and Fullscript partner to simplify lab ordering and results management, helping providers deliver faster, more connected care.</description>
</item>
<item>
<title>Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-speak-44th-annual-j-211500846</link>
<guid isPermaLink="true">https://6ix.com/company/laboratory-corporation-of-america-holdings/news/labcorp-speak-44th-annual-j-211500846</guid>
<pubDate>Tue, 30 Dec 2025 21:15:00 GMT</pubDate>
<description>Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, at 4:30 p.m. PT.</description>
</item>
</channel>
</rss>